open access

Vol 89, No 4 (2018)
Research paper
Published online: 2018-04-30
Get Citation

Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy

Magdalena Magnowska1, Natalia Iżycka1, Joanna Kapoła-Czyż2, Anna Romała2, Jakub Lorek1, Marek Spaczyński2, Ewa Nowak-Markwitz1
DOI: 10.5603/GP.a2018.0034
·
Pubmed: 29781075
·
Ginekol Pol 2018;89(4):201-205.
Affiliations
  1. Department of Gynecology, Obstetrics and Gynecologic Oncology, Division of Gynecologic Oncology, Poznan University of Medical Sciences, Poznan, Poland
  2. Student’s Scientific Society by the Division of Gynecologic Oncology, Poznan University of Medical Science, Polna 33, 60-535 Poznan, Poland

open access

Vol 89, No 4 (2018)
ORIGINAL PAPERS Gynecology
Published online: 2018-04-30

Abstract

Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) is a common chemotherapy side effect, but its prevention and treatment remains a challenge. Neurotoxicity may lead to dose limitation or even treatment discontinuation, and therefore potentially affect the efficacy of anticancer treatment and long term outcomes. The practice to administer gabapentin for neuropathy may be applicable, but is limited by insufficient studies. The aim of our study was to assess the presence of chemotherapy-induced peripheral neuropathy in ovarian cancer patients treated with first-line paclitaxel and carboplatin chemotherapy and evaluate the effectiveness of gabapentin in treatment of this condition.

Material and methods: 61 ovarian cancer patients treated with first line chemotherapy were included in the study. The first phase of the study was to assess neurological condition of each patient by: neuropathy symptoms scale, McGill’s scale, neurological deficit and quality of life, during the chemotherapy. In the second phase of the study we evaluated the response to gabapentin treatment in a group of patients who developed neuropathy. Results: 78.7% of the patients developed chemotherapy related neuropathy. During the course of chemotherapy these patients experienced significant exacerbation of neuropathy symptoms (p < 0.0001), neuropathic pain (p < 0.0001), neurologic deficit (p < 0.0012) and worsening of quality of life (p < 0.0002). Patients who were qualified to undergo the gabapentin treatment observed improvement in symptoms (p < 0.027), pain (p < 0.027) and neurologic deficit (p < 0.019). Quality of life did not change significantly after gabapentin treatment (p < 0.128).

Conclusions: Chemotherapy substantially deteriorates the neurologic condition of the patients and the quality of life. Paclitaxel and carboplatin treated patients may benefit from gabapentin therapy in chemotherapy-induced peripheral neuropathy.

Abstract

Objectives: Chemotherapy-induced peripheral neuropathy (CIPN) is a common chemotherapy side effect, but its prevention and treatment remains a challenge. Neurotoxicity may lead to dose limitation or even treatment discontinuation, and therefore potentially affect the efficacy of anticancer treatment and long term outcomes. The practice to administer gabapentin for neuropathy may be applicable, but is limited by insufficient studies. The aim of our study was to assess the presence of chemotherapy-induced peripheral neuropathy in ovarian cancer patients treated with first-line paclitaxel and carboplatin chemotherapy and evaluate the effectiveness of gabapentin in treatment of this condition.

Material and methods: 61 ovarian cancer patients treated with first line chemotherapy were included in the study. The first phase of the study was to assess neurological condition of each patient by: neuropathy symptoms scale, McGill’s scale, neurological deficit and quality of life, during the chemotherapy. In the second phase of the study we evaluated the response to gabapentin treatment in a group of patients who developed neuropathy. Results: 78.7% of the patients developed chemotherapy related neuropathy. During the course of chemotherapy these patients experienced significant exacerbation of neuropathy symptoms (p < 0.0001), neuropathic pain (p < 0.0001), neurologic deficit (p < 0.0012) and worsening of quality of life (p < 0.0002). Patients who were qualified to undergo the gabapentin treatment observed improvement in symptoms (p < 0.027), pain (p < 0.027) and neurologic deficit (p < 0.019). Quality of life did not change significantly after gabapentin treatment (p < 0.128).

Conclusions: Chemotherapy substantially deteriorates the neurologic condition of the patients and the quality of life. Paclitaxel and carboplatin treated patients may benefit from gabapentin therapy in chemotherapy-induced peripheral neuropathy.

Get Citation

Keywords

chemotherapy, neuropathy, McGill’s scale, neurologic deficit, gabapentin

About this article
Title

Effectiveness of gabapentin pharmacotherapy in chemotherapy-induced peripheral neuropathy

Journal

Ginekologia Polska

Issue

Vol 89, No 4 (2018)

Article type

Research paper

Pages

201-205

Published online

2018-04-30

DOI

10.5603/GP.a2018.0034

Pubmed

29781075

Bibliographic record

Ginekol Pol 2018;89(4):201-205.

Keywords

chemotherapy
neuropathy
McGill’s scale
neurologic deficit
gabapentin

Authors

Magdalena Magnowska
Natalia Iżycka
Joanna Kapoła-Czyż
Anna Romała
Jakub Lorek
Marek Spaczyński
Ewa Nowak-Markwitz

References (13)
  1. Argyriou AA, Bruna J, Marmiroli P, et al. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol. 2012; 82(1): 51–77.
  2. Iżycki D, Niezgoda AA, Kaźmierczak M, et al. Chemotherapy-induced peripheral neuropathy - diagnosis, evolution and treatment. Ginekol Pol. 2016; 87(7): 516–521.
  3. Tanabe Y, Hashimoto K, Shimizu C, et al. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013; 18(1): 132–138.
  4. Hershman DL, Lacchetti C, Loprinzi CL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(18): 1941–1967.
  5. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain . 2010; 150(3): 573–581.
  6. Mishra S, Bhatnagar S, Goyal GN, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care. 2012; 29(3): 177–182.
  7. Sills GJ. The mechanisms of action of gabapentin and pregabalin. Curr Opin Pharmacol. 2006; 6(1): 108–113.
  8. Park SB, Kwok JB, Loy CT, et al. Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer. 2014; 14: 993.
  9. Ezendam NPM, Pijlman B, Bhugwandass C, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014; 135(3): 510–517.
  10. Hershman DL, Lacchetti C, Loprinzi CL, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(18): 1941–1967.
  11. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007; 110(9): 2110–2118.
  12. Cata JP, Weng HR, Lee BN, et al. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol. 2006; 72(3): 151–169.
  13. Park HJ. Chemotherapy induced peripheral neuropathic pain. Korean J Anesthesiol. 2014; 67(1): 4–7.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl